Karamitopoulou E, Perentes E, Diamantis I, Vogt U, Wegmann W
Cantonal Institute of Pathology, Liestal, Switzerland.
Histopathology. 1995 Dec;27(6):517-23. doi: 10.1111/j.1365-2559.1995.tb00322.x.
The immunohistochemical expression of the p53 gene product was examined in 91 colorectal adenomas from patients without (group 1, 50 cases) or with (group 2, 41 cases) concurrent sporadic colorectal carcinoma, and in 15 additional cases of randomly selected carcinomas from group 2 patients. Immunohistochemical reactions were performed with the DO-7 monoclonal and the CM1 polyclonal antibodies, following microwave irradiation of the tissues in an antigen retrieval solution, and the proportion of the immunoreactive cells was semiquantitatively assessed. p53 protein immunoreactivity was present in 46.1% (42, of 91, i.e., 20 out of 50 of group 1 and 22 out of 41 of group 2) and 33% (30 of 91, i.e. 14 out of 50 of group 1 and 16 out of 41 of group 2) of the adenomas using DO-7 and CM1 antibody, respectively. High p53 expression (i.e. immunolabelling of more than 30% of the tumour cell nuclei) was found in 13.2% of the adenomas (12 of 91, i.e. three out of 50 of group 1 and nine out of 41 of group 2; P = 0.025 using the chi 2 test) using the DO-7 antibody, and in 6.6% of the cases (six of 91, i.e. two out of 50 of group 1 and four out of 41 of group 2) using the CM1 antibody. In carcinomas, 80% of the cases (i.e. 12 of 15) were found to express p53 protein with both antibodies. p53 immunoreactivity in colorectal adenomas increased with the degree of dysplasia: only five (17.8%) of the 28 adenomas with mild dysplasia were found to be DO-7 positive, while all of them remained CM1 negative. From the 50 adenomas exhibiting moderate dysplasia, 28 (56%) were DO-7 positive, and 22 (44%) were CM1 positive. Finally, from the 13 adenomas with severe dysplasia, nine (69.2%) and eight (61.5%) were found to be positive with the DO-7 and the CM1 antibody, respectively. Our results indicate that an increased number of group 2 adenomas express p53 protein, when compared with group 1 adenomas, and suggest that a strong correlation exists between p53 protein expression and the degree of dysplasia in colorectal neoplasms.
对91例大肠腺瘤患者(其中无合并散发性大肠癌的患者50例为第1组,合并散发性大肠癌的患者41例为第2组)以及从第2组患者中随机选取的另外15例癌组织进行了p53基因产物的免疫组化表达检测。组织经抗原修复液微波照射后,用DO-7单克隆抗体和CM1多克隆抗体进行免疫组化反应,并对免疫反应细胞的比例进行半定量评估。使用DO-7抗体时,46.1%(91例中的42例,即第1组50例中的20例和第2组41例中的22例)的腺瘤存在p53蛋白免疫反应性;使用CM1抗体时,该比例为33%(91例中的30例,即第1组50例中的14例和第2组41例中的16例)。使用DO-7抗体时,13.2%的腺瘤(91例中的12例,即第1组50例中的3例和第2组41例中的9例;卡方检验P = 0.025)出现高p53表达(即肿瘤细胞核免疫标记超过30%);使用CM1抗体时,该比例为6.6%(91例中的6例,即第1组50例中的2例和第2组41例中的4例)。在癌组织中,80%的病例(15例中的12例)两种抗体检测均显示p53蛋白表达。大肠腺瘤中的p53免疫反应性随发育异常程度增加而升高:28例轻度发育异常的腺瘤中仅5例(17.8%)DO-7阳性,且均为CM1阴性。50例中度发育异常的腺瘤中,28例(56%)DO-7阳性,22例(44%)CM1阳性。最后,13例重度发育异常的腺瘤中,分别有9例(69.2%)和8例(61.5%)DO-7和CM1抗体检测呈阳性。我们的结果表明,与第1组腺瘤相比,第2组腺瘤中表达p53蛋白的数量增加,提示p53蛋白表达与大肠肿瘤发育异常程度之间存在强相关性。